


글로벌 제약사 파이프라인 분석

- Sanofi -

2022.06.

국가신약개발사업단


• 질환별 파이프라인



sanofi

질환분야	개수	비중
Immunology	30	33%
Oncology	30	33%
Infectious	10	11%
Neuroscience	7	8%
Hematology	6	7%
Metabolic	3	4%
Renal	2	2%
Musculoskeletal	1	1%
Others	1	1%
합계	90개	100%

• 물질별 파이프라인



sanofi

물질	개수	비중
Antibody	41	46%
Small molecules	22	24%
Protein	9	10%
Vaccine	9	10%
ADC	5	6%
RNA	3	3%
Cell Therapy	1	1%
합계	90개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Hematology	Phase 3	BIVV001		efanesocto cog alfa	Hemophilia A	Protein	Coagulation Factor VIII	Coagulation Factor VIII replacement	Mono	Sobi
2	Hematology	Phase 3			fitusiran	Hemophilia A and B, pediatric	RNA	anti-thrombin III	anti-thrombin III inhibitor	Mono	Alnylam
3	Hematology	Phase 2	SAR650984	Sarclisa	isatuximab-irfc	Warm Autoimmune Hemolytic Anemia	Antibody	CD38	Cytotoxic to cells expressing CD38	Mono	-
4	Hematology	Phase 3	PRN1008		rilzabrutinib	Immune Thrombocytopenia	Small molecules	BTK	BTK inhibitor	Mono	-
5	Hematology	Phase 2	PRN1008		rilzabrutinib	Warm Autoimmune Hemolytic Anemia	Small molecules	BTK	BTK inhibitor	Mono	-
6	Hematology	Phase 2	SAR445088			Cold Agglutinin Disease	Antibody	Complement 1(C1) esterase	C1 inhibitor	Mono	-
7	Immunology	Phase 2	KY1005		amlitelimab	Atopic Dermatitis	Antibody	OX40L	OX40L inhibitor	Mono	-
8	Immunology	Registration	SAR231893	Dupixent	dupilumab	Atopic dermatitis (6 months-5 years old)	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
9	Immunology	Registration	SAR231893	Dupixent	dupilumab	Eosinophilic esophagitis	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
10	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Chronic pruritis of unknown origin	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
11	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Prurigo nodularis	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
12	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Bullous pemphigoid	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
13	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Chronic spontaneous urticaria	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
14	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Chronic obstructive pulmonary disease	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
15	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Chronic inducible cold urticaria	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
16	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Chronic rhinosinusitis without nasal polyps	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
17	Immunology	Phase 3	SAR231893	Dupixent	dupilumab	Allergic fungal rhinosinusitis	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
18	Immunology	Phase 2	SAR231893	Dupixent	dupilumab	Peanut allergy	Antibody	IL-4/IL-13	IL-4 Receptor Subunit Alpha (CD124 or IL4R) and IL-13 Antagonist	Mono	Regeneron
19	Immunology	Phase 2	SAR443122		eclitasertib	Cutaneous Lupus Erythematosus	Small molecules	RIPK1	RIPK1 inhibitor	Mono	Denali
20	Immunology	Phase 3			itepekimab	Chronic obstructive pulmonary disease	Antibody	IL-33	IL-33 inhibitor	Mono	Regeneron

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
21	Immunology	Phase 2	PRN1008		rilzabrutinib	Atopic Dermatitis	Small molecules	BTK	BTK inhibitor	Mono	-
22	Immunology	Phase 2	PRN1008		rilzabrutinib	IgG4-related disease	Small molecules	BTK	BTK inhibitor	Mono	-
23	Immunology	Phase 2	PRN1008		rilzabrutinib	Asthma	Small molecules	BTK	BTK inhibitor	Mono	-
24	Immunology	Phase 2	PRN1008		rilzabrutinib	Chronic spontaneous urticaria	Small molecules	BTK	BTK inhibitor	Mono	-
25	Immunology	Phase 2	SAR153191	Kevzara	sarilumab	Polyarticular juvenile idiopathic arthritis	Antibody	IL-6	IL-6 antagonist	Mono	Regeneron
26	Immunology	Phase 2	SAR153191	Kevzara	sarilumab	Systemic juvenile arthritis	Antibody	IL-6	IL-6 antagonist	Mono	Regeneron
27	Immunology	Phase 2	SAR441344			Sjögren's Syndrome	Antibody	CD40L	CD40L inhibitor	Mono	Immunext
28	Immunology	Phase 2	SAR441344			Systemic Lupus Erythematosus	Antibody	CD40L	CD40L inhibitor	Mono	Immunext
29	Immunology	Phase 2	SAR444727			Atopic Dermatitis	Small molecules	BTK	BTK inhibitor	Mono	-
30	Immunology	Phase 1	SAR441566			Inflammatory indications	Small molecules	TNF	TNF inhibitor	Mono	-
31	Immunology	Phase 1	SAR442970			Inflammatory indications	Antibody	TNFα/OX40L	TNFα/OX40L inhibitor	Mono	-
32	Immunology	Phase 1	SAR442999			Inflammatory indications	Antibody	TNFα/IL-23	TNFα/IL-23 inhibitor	Mono	-
33	Immunology	Phase 1	SAR443726			Atopic dermatitis	Antibody	IL-13/OX40L	IL-13/OX40L inhibitor	Mono	-
34	Immunology	Phase 1	SAR443765			Inflammatory indication	Antibody	IL-13/TSLP	IL-13/TSLP inhibitor	Mono	-
35	Immunology	Phase 1	SAR444336			Inflammatory indication	Protein	IL-2 receptor	Pegylated IL-2 receptor agonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
36	Immunology	Phase 1	SAR444656			Atopic dermatitis	Small molecules	IRAK4	IRAK4 degrader	Mono	Kymera
37	Infectious	Registration	SP0232		nirsevimab	Respiratory Syncytial Virus	Antibody	RSV F protein	RSV F protein inhibitor	Mono	AstraZeneca
38	Infectious	Registration	SP0253			COVID-19	Vaccine	Novel Corona Virus Spike Glycoprotein (E2 or Peptomer Protein or S)	Recombinant baculovirus vaccine	Mono	GSK
39	Infectious	Phase 3		MenQuadfi		Meningitis, 6 weeks+	Vaccine	Meningococcal Capsular Polysaccharide Antigen	Conjugate vaccine	Mono	-
40	Infectious	Phase 3		VerorabVax		Rabies	Vaccine	N/A	Purified Vero rabies vaccine	Mono	-
41	Infectious	Phase 2	SP0125			Respiratory syncytial virus (toddler)	Vaccine	N/A	Live attenuated virus vaccine	Mono	-
42	Infectious	Phase 2	SP0202			Pneumococcal infections	Vaccine	N/A	conjugate vaccine	Mono	-
43	Infectious	Phase 2	SP0218			Yellow Fever	Vaccine	N/A	Vaccine (Vero cell)	Mono	-
44	Infectious	Phase 2	SP0230			Meningitis B	Vaccine	N/A	Multicomponent vaccine	Mono	-
45	Infectious	Phase 2		Fluzone		Pediatric flu	Vaccine	N/A	Inactivated influenza vaccine	Mono	-
46	Infectious	Phase 1	SP0273			Influenza	Vaccine	Hemagglutinin HA	mRNA vaccine	Mono	-
47	Metabolic	Phase 3	GZ402666	Nexviazyme	avalglucosidase alfa	Pompe disease, infantile onset	Protein	Lysosomal Alpha Glucosidase	Enzyme replacement therapy (GAA)	Mono	-
48	Metabolic	Phase 2	GZ402671		venglustat	Fabry disease	Small molecules	Glucosyltransferase(GCS)	Oral GCS inhibitor	Mono	-
49	Metabolic	Phase 2	GZ402671		venglustat	Gaucher disease type 3	Small molecules	Glucosyltransferase(GCS)	Oral GCS inhibitor	Mono	-
50	Musculoskeletal	Phase 1	SAR442501			Achondroplasia	Antibody	FGFR3	FGFR3 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
51	Neuroscience	Phase 3	SAR442168		tolebrutinib	Relapsing Multiple Sclerosis	Small molecules	BTK	BTK inhibitor	Mono	-
52	Neuroscience	Phase 3	SAR442168		tolebrutinib	Primary Progressive Multiple Sclerosis	Small molecules	BTK	BTK inhibitor	Mono	-
53	Neuroscience	Phase 3	SAR442168		tolebrutinib	Secondary Progressive Multiple Sclerosis	Small molecules	BTK	BTK inhibitor	Mono	-
54	Neuroscience	Phase 3	SAR442168		tolebrutinib	Myasthenia Gravis	Small molecules	BTK	BTK inhibitor	Mono	-
55	Neuroscience	Phase 2	SAR441344			Multiple sclerosis	Antibody	CD40L	CD40L inhibitor	Mono	Immunext
56	Neuroscience	Phase 2	SAR445088			CIDP	Antibody	Complement 1(C1) esterase	C1 inhibitor	Mono	-
57	Neuroscience	Phase 1	SAR443820			Amyotrophic Lateral Sclerosis	Small molecules	RIPK1	RIPK1 inhibitor	Mono	Denali
67	Oncology	Phase 2	KY1044		alomfilimab	Solid tumors	Antibody	ICOS	ICOS agonist	Mono	-
60	Oncology	Phase 3	SAR439859		amcenestrant	Adjuvant breast cancer	Small molecules	estrogen receptor	SERD(selective estrogen receptor degrader)	Mono	-
61	Oncology	Phase 3	SAR439859		amcenestrant	1L metastatic breast cancer	Small molecules	estrogen receptor	SERD + palbociclib	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
61	Oncology	Registration	SAR439684	Libtayo	cemiplimab-rwlc	1L NSCLC	Antibody	PD-1	PD-1 Antagonist	Mono	Regeneron
62	Oncology	Registration	SAR439684	Libtayo	cemiplimab-rwlc	2L cervical cancer	Antibody	PD-1	PD-1 Antagonist	Mono	Regeneron
63	Oncology	Phase 3	SAR439684	Libtayo	cemiplimab-rwlc	Adjuvant CSCC	Antibody	PD-1	PD-1 Antagonist	Mono	Regeneron
64	Oncology	Phase 3	SAR650984	Sarclisa	isatuximab-irfc	1L newly diagnosed Multiple Myeloma Ti	Antibody	CD38	Cytotoxic to cells expressing CD38	Combination	-
65	Oncology	Phase 3	SAR650984	Sarclisa	isatuximab-irfc	1L newly diagnosed Multiple Myeloma Te	Antibody	CD38	Cytotoxic to cells expressing CD38	Combination	-
66	Oncology	Phase 3	SAR650984	Sarclisa	isatuximab-irfc	Smoldering Multiple Myeloma	Antibody	CD38	Cytotoxic to cells expressing CD38	Combination	-
67	Oncology	Phase 2	SAR650984	Sarclisa	isatuximab-irfc	Relapsed/refractory Multiple Myeloma	Antibody	CD38	Cytotoxic to cells expressing CD38	Combination	-
68	Oncology	Phase 2	SAR650984	Sarclisa	isatuximab-irfc	1-2L Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia, pediatrics	Antibody	CD38	Cytotoxic to cells expressing CD38	Mono	-
69	Oncology	Phase 3	SAR408701		tusamitamab ravtansine	2/3L NSCLC	ADC	CEACAM5	Cytotoxic to cells expressing CEACAM5	Mono	-
70	Oncology	Phase 2			tusamitamab ravtansine	1L NSCLC	ADC	CEACAM5	Cytotoxic to cells expressing CEACAM5	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
71	Oncology	Phase 2			tusamitamab ravtansine	2/3L NSCLC	ADC	CEACAM5	Cytotoxic to cells expressing CEACAM5	Mono	-
72	Oncology	Phase 2			tusamitamab ravtansine	Exploratory solid tumors	ADC	CEACAM5	Cytotoxic to cells expressing CEACAM5	Mono	-
73	Oncology	Phase 2			tusamitamab ravtansine	Gastric cancer	ADC	CEACAM5	Cytotoxic to cells expressing CEACAM5	Mono	-
74	Oncology	Phase 2	SAR442720			2L NSCLC	Small molecules	SHP2	SHP2 inhibitor + KRAS inhibitor	Combination	Revolution Medicines
75	Oncology	Phase 2	SAR444245			Skin cancers	Protein	IL-2 receptor	Non-alpha IL-2 + cemiplimab	Combination	-
76	Oncology	Phase 2	SAR444245			NSCLC/Mesothelioma	Protein	IL-2 receptor	Non-alpha IL-2 + combinations	Combination	-
77	Oncology	Phase 2	SAR444245			Head & Neck tumors	Protein	IL-2 receptor	Non-alpha IL-2 + combinations	Combination	-
78	Oncology	Phase 2	SAR444245			Lymphoma	Protein	IL-2 receptor	Non-alpha IL-2 + combinations	Combination	-
79	Oncology	Phase 2	SAR444245			Gastrointestinal cancer	Protein	IL-2 receptor	Non-alpha IL-2 + combinations	Combination	-
80	Oncology	Phase 1	SAR441000			Solid tumors	RNA	N/A	Cytokine mRNA	Mono	BioNTech

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
81	Oncology	Phase 1	SAR442257			Multiple myeloma / Non-Hodgkin lymphoma	Antibody	CD38xCD28xCD3	CD38xCD28xCD3 antagonist	Mono	-
82	Oncology	Phase 1	SAR442720			Solid tumors	Small molecules	SHP2	SHP2 inhibitor + pembrolizumab	Combination	Revolution Medicines
83	Oncology	Phase 1	SAR443216			Gastric cancer	Antibody	CD3xCD28xHER2	CD3xCD28xHer2 agonist	Mono	-
84	Oncology	Phase 1	SAR443579			Acute Myeloid Leukemia	Antibody	NKp46/CD123	NKp46/CD123 agonist	Mono	Innate Pharma
85	Oncology	Phase 1	SAR444881			Solid tumors	Antibody	ILT2	ILT2 antagonist	Mono	Biond
86	Oncology	Phase 1	SAR445419			Acute Myeloid Leukemia	Cell Therapy	IL-21 receptor	NK cell therapy	Mono	-
87	Oncology	Phase 1	SAR445710			Solid tumors	Protein	PD-L1/IL-15	PD-L1/IL-15 inhibitor	Mono	-
88	Renal	Phase 2	SAR339375			Alport syndrome	RNA	MicroRNA-21	Antisense therapy	Mono	-
89	Renal	Phase 1	SAR443809			Rare renal diseases	Antibody	Factor Bb	Factor Bb inhibitor	Mono	-
90	Others	Phase 3	GZ402671		venglustat	GM2 Gangliosidosis	Small molecules	Glucosyltransferase (GCS)	Oral GCS inhibitor	Mono	-

자료: Sanofi 홈페이지, BioCentury, GlobalData